GNT Eyes Unmet Need As Novel Ischemic Stroke Therapy Moves To Phase III
Breaks New Ground For Korean Pharma
Korea's GNT Pharma is set to take its first-in-class, multi-targeted stroke therapy Nelonemdaz into Phase III, raising hopes for a new treatment that could sharply reduce disabilities and death in stroke patients.
